Compare State Street SPDR S&P Biotech ETF (XBI) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Block Inc — how do they compare? State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B), while Block Inc trades at $77.24 (market cap $45.20B). The key difference: Block Inc is far larger — about 4.5× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is more actively traded (12,903,266 versus 8,386,094). Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR S&P Biotech ETF for 38 Days and Block Inc for 78 Days on average.
| XBI | XYZ | |
|---|---|---|
Market Cap | $10.11B | $45.20B |
Volume | 12,903,266 | 8,386,094 |
Sector | Broad Market / Factor | Technology |
52-Week High | $169.55 | $84.85 |
52-Week Low | $104.99 | $49.04 |
Typical Hold Time | 38 Days | 78 Days |
Enterprise Value | — | $40.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
XYZ trades at $75.21, down 1.13% on the day, with technical indicators showing bearish momentum near key support at $74. The company reported mixed Q3 2026 earnings with two beats and one miss, while revenue growth has slowed to 0.4% year-over-year in 2025. Analyst consensus remains strongly bullish with a $97.47 price target, representing 30% upside potential from current levels.
XYZ faces valuation concerns with a high P/E ratio of 134.34, though strong institutional support and expanding merchant partnerships provide growth catalysts. Key risks include declining net income margins and negative cash flow trends, requiring careful monitoring of upcoming Q3 2026 results for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
